Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Cipramil (citalopram) low level of drug-drug interactions is benefit for elderly, annual report says.

Executive Summary

FOREST TOUTS CIPRAMIL (CITALOPRAM) LOW LEVEL OF DRUG-DRUG INTERACTIONS in its recently-released annual report for fiscal 1997 (ended March 31). Forest filed an NDA for the selective serotonin reuptake inhibitor, licensed from the Danish firm H. Lundbeck, on May 12 under the brand name Cipramil ("The Pink Sheet" May 19, In Brief). "Recent data indicates that among the SSRIs, citalopram may be least likely to cause potential drug-drug interactions," Forest maintained in the annual report. Wyeth's promotions discussing Effexor's drug-drug interaction potential recently were cited by FDA's ad division.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel